Drug Profile
Research programme: antibody therapeutics - Innovative Targeting Solutions/Janssen Biotech
Alternative Names: HuTARG antibodies - Innovative Targeting Solutions/Janssen BiotechLatest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Innovative Targeting Solutions
- Developer Innovative Targeting Solutions; Janssen Biotech
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Autoimmune-disorders in Canada (Parenteral)
- 28 Sep 2020 No recent reports of development identified for research development in Autoimmune-disorders in USA (Parenteral)
- 28 Sep 2020 No recent reports of development identified for research development in Cancer in Canada (Parenteral)